Loading…
TScan Therapeutics, Inc. is projected to decline to $0.6979 by 2027, a -4% move from its current price of $0.7234. TCRX is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/4/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $0.6912 | $0.7234 | $0.7571 | 0.00% |
| Aug 6 | $0.6783 | $0.7234 | $0.7716 | +0.01% |
| Aug 7 | $0.6686 | $0.7235 | $0.7829 | +0.01% |
| Aug 8 | $0.6605 | $0.7235 | $0.7925 | +0.01% |
| Aug 9 | $0.6534 | $0.7235 | $0.8011 | +0.02% |
| Aug 10 | $0.6471 | $0.7235 | $0.809 | +0.02% |
| Aug 11 | $0.6414 | $0.7236 | $0.8163 | +0.02% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.6414 | $0.7236 | $0.8163 | +0.02% |
| Week 2 | $0.6103 | $0.7237 | $0.8583 | +0.05% |
| Week 3 | $0.5875 | $0.7239 | $0.892 | +0.07% |
| Week 4 | $0.569 | $0.7241 | $0.9215 | +0.10% |
| Week 5 | $0.5531 | $0.7243 | $0.9483 | +0.12% |
| Week 6 | $0.5392 | $0.7244 | $0.9733 | +0.14% |
| Week 7 | $0.5267 | $0.7246 | $0.9968 | +0.17% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
TScan Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing T cell receptor-engineered T cell (TCR-T) therapies for cancer in the United States. It is headquartered in Waltham, Massachusetts and was incorporated in 2018.
Its lead product is TSC-101, for the treatment of patients with AML, MDS, and ALL in the setting of allogeneic hematopoietic cell transplantation, and it is in Phase I.
The company also develops TSC-102-A01 and TSC-102-A03, allogeneic and donor-derived TCR-T therapy candidates, as well as TSC-200 through TSC-204 for solid tumors. It has a research collaboration and license agreement with Amgen Inc. to identify antigens recognized by T cells in Crohn's disease.
TScan Therapeutics was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
TScan Therapeutics, Inc. (TCRX) is currently priced at $0.7683 per share, with a market capitalization of $50.21M, and it ranks 4362 by market cap. The current price and market position place it among smaller-cap biotech equities with a clinical-stage focus.
Near-term price action is expected to be muted, with a mixed near-term outlook reflected in the forecast, which shows neutral to modestly evolving levels through 2026-2029.
Longer-term projections become more favorable, with bullish momentum indicated from 2030 onward as average prices rise and ROI climbs, culminating in substantial upside by 2050. The forecast highlights notable upside potential in the 2030-2050 horizon, though these are estimates and not guarantees.
A major floor 45.1% below — a decisive break under it would weaken the trend.
Price is testing support right now (2.6% away) — a key level to hold.
The nearest ceiling, 74.2% above — a clean break opens room to run.
A major ceiling 98.1% above — clearing it would confirm fresh momentum.
Key TCRX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of TCRX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.7566 | Sell | $0.7664 | Sell |
| MA 10 | $0.8188 | Sell | $0.8101 | Sell |
| MA 20 | $0.9207 | Sell | $0.8695 | Sell |
| MA 50 | $0.953 | Sell | $0.9472 | Sell |
| MA 100 | $1.04 | Sell | $1.02 | Sell |
| MA 200 | $1.13 | Sell | $1.22 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 34.54 | Neutral |
| Stoch RSI (14) | 6.41 | Buy |
| CCI (20) | -110.70 | Sell |
| Williams %R (14) | -99.49 | Info |
| MACD (12,26,9) | -0.02 | Sell |
| ROC (12) | -19.50 | Sell |
| Bollinger %B (20,2) | 0.17 | Neutral |
| Stochastic %K (14) | 0.51 | Buy |
| TRIX (15) | -0.62 | Sell |
| Awesome (5,34) | -0.17 | Sell |
| Ultimate (7,14,28) | 16.53 | Buy |
| Momentum (10) | -0.17 | Sell |
| Aroon Osc (25) | -60.00 | Sell |
| Hull MA (9) | 0.72 | Buy |
| ADX (14) | 19.68 | Neutral |
| ATR (14) | 0.04 | Info |
The 30-day technical picture currently shows bearish sentiment. RSI14 is 40, signaling cautious momentum. The stock trades near the SMA50 of $0.9742 and below the SMA200 of $1.15, suggesting near-term pressure.
Key near-term levels to monitor include support at $0.768 and resistance at $1.26, with the 30-day trading range spanning $0.5508 to $1.07.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.7234 | $0.7234 | $0.9629 | 0% | Neutral | |
| $0.523 | $0.6979 | $1.00 | -4% | Neutral | |
| $0.443 | $0.622 | $0.9458 | -14% | Neutral | |
| $0.4805 | $0.7041 | $1.12 | -3% | Neutral | |
| $0.5938 | $0.9043 | $1.49 | +25% | Bullish | |
| $0.5709 | $0.9008 | $1.53 | +25% | Bullish | |
| $0.5987 | $0.9771 | $1.71 | +35% | Bullish | |
| $0.568 | $0.9571 | $1.72 | +32% | Bullish | |
| $0.4688 | $0.8147 | $1.49 | +13% | Neutral | |
| $0.5251 | $0.9404 | $1.76 | +30% | Bullish | |
| $0.5573 | $1.15 | $2.35 | +59% | Bullish | |
| $1.15 | $2.56 | $5.89 | +254% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $0.7234 | $0.7234 | $0.9195 | +0.00% |
| September 2026 | $0.6323 | $0.7622 | $0.9545 | +5.36% |
| October 2026 | $0.595 | $0.7257 | $0.9248 | -4.79% |
| November 2026 | $0.5825 | $0.7172 | $0.9269 | -1.16% |
| December 2026 | $0.5923 | $0.7358 | $0.9629 | +2.59% |
Click any year to see its month-by-month TCRX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The TCRX price prediction for 2026 points to an average of $0.7234 (low $0.7234, high $0.9629) — a potential gain of 0% on today's $0.7234. Price action looks broadly range-bound.
In 2027, TCRX is projected to trade between $0.523 and $1.00, averaging $0.6979 — a potential decline of -4% from today's $0.7234. That is -4% versus the projected 2026 average. A consolidation phase looks the most probable path here.
TScan Therapeutics, Inc.'s 2028 outlook centres on $0.622, within a $0.443 to $0.9458 range. That is -11% versus the projected 2027 average. That marks a -14% change versus current levels. Price action looks broadly range-bound.
By 2029, TCRX could reach as high as $1.12, with a base case around $0.7041 and support toward $0.4805 — roughly -3% from $0.7234. A consolidation phase looks the most probable path here.
Expect TCRX to range from $0.5938 to $1.49 through 2030. The $0.9043 average target implies a +25% move from current prices. That is up +28% on the projected 2029 average. Momentum favours further upside here.
The TCRX price prediction for 2031 points to an average of $0.9008 (low $0.5709, high $1.53) — a potential gain of +25% on today's $0.7234. Buyers look set to stay in control over this stretch.
In 2032, TCRX is projected to trade between $0.5987 and $1.71, averaging $0.9771 — a potential gain of +35% from today's $0.7234. That is up +8% on the projected 2031 average. Momentum favours further upside here.
TScan Therapeutics, Inc.'s 2033 outlook centres on $0.9571, within a $0.568 to $1.72 range. That is -2% versus the projected 2032 average. That marks a +32% change versus current levels. Buyers look set to stay in control over this stretch.
By 2034, TCRX could reach as high as $1.49, with a base case around $0.8147 and support toward $0.4688 — roughly +13% from $0.7234. Price action looks broadly range-bound.
Expect TCRX to range from $0.5251 to $1.76 through 2035. The $0.9404 average target implies a +30% move from current prices. That is up +15% on the projected 2034 average. Buyers look set to stay in control over this stretch.
The TCRX price prediction for 2040 points to an average of $1.15 (low $0.5573, high $2.35) — a potential gain of +59% on today's $0.7234. Momentum favours further upside here.
In 2050, TCRX is projected to trade between $1.15 and $5.89, averaging $2.56 — a potential gain of +254% from today's $0.7234. That is up +123% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in TCRX today (≈ 1,382.361073 TCRX) could be worth
$3,539.93
+$2,539.93 (+254%) by 2050 · US Dollar
Based on the average projected TCRX price of $2.56 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in TCRXwould be worth at today's price.
$1,000 invested in TCRX on Jul 31, 2025 (≈ 574.712641 TCRX) would be worth
$415.75
-$584.25 (-58.4%) today · 0.42× · US Dollar
Based on a TCRX entry price of $1.74 vs. today's $0.7234.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.794 | $911.08 | -8.9% |
| 1 month ago | $1.07 | $676.07 | -32.4% |
| 3 months ago | $1.22 | $592.95 | -40.7% |
| 6 months ago | $1.02 | $709.22 | -29.1% |
| 1 year ago | $1.74 | $415.75 | -58.4% |
| All time (5.0y) ago | $10.75 | $67.29 | -93.3% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our TCRX forecast.
Our base-case forecast reaches $1.40 around 2050.
Implied market cap at $1.40: $85.5M
The multi-year forecast shows a neutral stance through 2026-2029, with 2026 avg $0.7683, min $0.768, max $1.04 and ROI 0, 2027 avg $0.7191, min $0.5289, max $1.06 and ROI -6.4, 2028 avg $0.6547, min $0.4547, max $1.02 and ROI -14.8, and 2029 avg $0.7359, min $0.4868, max $1.20 and ROI -4.2.
From 2030 onward, the forecast turns bullish: 2030 avg $0.9489, min $0.6008, max $1.61 with ROI 23.5 and sentiment BULLISH; 2031 avg $0.962, min $0.5847, max $1.69 with ROI 25.2 and sentiment BULLISH; 2032 avg $1.04, min $0.6069, max $1.88 with ROI 35.1 and sentiment BULLISH; 2033 avg $0.9981, min $0.5621, max $1.86 with ROI 29.9 and sentiment BULLISH.
The bullish trend continues into 2040 with avg $1.20, min $0.5405, max $2.57 and ROI 56.3; into 2050 with avg $2.69, min $1.21, max $6.19 and ROI 250.2, both years marked as BULLISH. While these figures provide a directional view, they are estimates and not guarantees. Investors should acknowledge the inherent uncertainty in long-term forecasts and monitor evolving clinical outcomes and market conditions.
Tap a question to reveal the answer.
2030 forecast shows an average price of $0.9489 with a max of $1.61 and a min of $0.6008, an ROI of 23.5, and a bullish sentiment.
Near-term forecasts are Neutral (e.g., 2026 avg $0.7683 with ROI 0). Longer-term forecasts are Bullish from 2030 onward, but these are estimates and not guarantees.
The forecast shows a max of $2.57 by 2040 and a max of $6.19 by 2050, with a 2050 average of $2.69, indicating potential to exceed $2 in the longer term.
The current price is $0.7683.
Bearish sentiment; RSI 40; SMA50 $0.9742; SMA200 $1.15; 30-day range $0.5508-$1.07; support $0.768; resistance $1.26.
TScan Therapeutics, Inc. Community Discussion
0Share your TScan Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.